Merck Serono Has Named Dr. John Orloff As Head Of Global Clinical Development

Name: John Orloff, MD 

Title: Head of Global Clinical Development, Merck Serono 


Dr. John Orloff will lead the design and execution of Merck Serono's global clinical development programs and projects, driving quality execution of the projects after proof-of-concept (POC). 

He will also oversee pipeline management and development, working collaboratively with the research teams, commercial partners and Medical Affairs to drive the efficient development of Merck's portfolio. 

Industry Experience: 

Dr. Orloff comes to Merck Serono from Novartis Pharma AG where he was Senior Vice President and Chief Medical Officer, responsible for leading all processes within Global Development as well as ensuring quality control and regulatory compliance, and driving innovative solutions to support business needs. 

Prior to that at Novartis, Dr. Orloff was Senior Vice President and Head, US Medical & Regulatory Affairs, serving on the executive leadership front across Clinical Development, Medical Affairs, and Evidence-based Medicine (Health Economics and Outcomes Research) for the US organization, as well as Regulatory Affairs for North America. 

Prior to Novartis, Dr. Orloff was Senior Director of the Bone Group, Endocrinology & Metabolism at Merck Research Labs, supporting clinical development of products for bone related disorders including osteoporosis and arthritis. 

Dr. Orloff received his undergraduate degree from Dartmouth College, and his MD from the University Of Vermont College Of Medicine. He completed his residency at the University of Pittsburgh, and started his career in academic medicine at Yale University as a Fellow in Endocrinology & Metabolism. 


Heather Connor
Head of R&D and Business Development Communications, Merck Serono
Ph: 978-294-1660
E-mail: [email protected] 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.